News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eagle Pharmaceuticals (EGRX) Reports Second Quarter 2014 Results


5/14/2014 7:14:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX) today announced its financial results for the three-month period ended March 31, 2014. This marks the first period for which Eagle is reporting financial results as a public company. Second quarter 2014 highlights include:

•PDUFA (“Prescription Drug User Fee Act”) date of July 6, 2014 set for bendamustine Ready-to-Dilute (“RTD”) for the treatment of Chronic Lymphocytic Leukemia (“CLL”) and indolent B-cell Non-Hodgkin’s Lymphoma (“NHL”).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES